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ABSTRACT
Aims The aim of this study was to observe the
percentage of thromboembolic and haemorrhagic events
over a 2-year follow-up in patients with non-valvular
atrial ﬁbrillation (NVAF) undergoing closure of the left
atrial appendage (LAA) with an occlusion device.
Observed events and CHADS2 (congestive heart failure,
hypertension, age, diabetes, stroke history), CHA2DS2-
VASc (also adding: vascular disease and sex) and HAS-
BLED (hypertension, abnormal liver/renal function, stroke
history, bleeding predisposition, labile international
normalised ratios, elderly, drugs/alcohol use)-predicted
events were compared.
Methods LAA closure with an occlusion device was
performed in 167 NVAF patients contraindicated for oral
anticoagulants and recruited from 12 hospitals between
2009 and 2013. At least two transoesophageal
echocardiograms were performed in the ﬁrst 6 months
postimplantation. Antithrombotics included clopidogrel
and aspirin. Patients were monitored for death, stroke,
major and relevant bleeding and hospitalisation for
concomitant conditions. Mean age was 74.68±8.58,
median follow-up was 24 months, 5.38% had
intraoperative complications and implantation was
successful in 94.6% of subjects. Mortality during follow-
up was 10.8%, mostly (9.5%) non-cardiac related.
Bleeding occurred in 10.1% of subjects, 5.7% major
and 4.4% minor though relevant, and 4.4% suffered
stroke. Major bleeding and stroke/transient ischaemic
attack events within 2 years (annual event rates, 290
patients/year) were less frequent than expected from
CHADS2 (2.4% vs 9.6%), CHA2DS2-VASc (2.4% vs
8.3%) and HAS-BLED (3.1% vs 6.6%) risk scores
(p<0.001, p=0.003, p=0.047, respectively).
Conclusions LAA closure with an occlusion device in
patients contraindicated for oral anticoagulants is a
therapeutic option associated with fewer
thromboembolic and haemorrhagic events than expected
from risk scores, particularly in the second year
postimplantation.
INTRODUCTION
In recent years, four new oral anticoagulants
(OACs) have shown advantages over warfarin in
the prevention of thromboembolic complications in
non-valvular atrial ﬁbrillation (NVAF). Although
their main advantages (reduction of intracranial
haemorrhage and no international normalised ratio
(INR) monitoring) are interesting, the risks inher-
ent to their anticoagulant action remain unchanged,
and they signiﬁcantly increase the cost of surgery.
The relative reduction in the number of events is
striking but less relevant in absolute terms.1
Closure of the left atrial appendage (LAA), the
site of over 90% of thrombi in these patients, has
initially been shown to reduce incidence of intra-
cranial haemorrhage. It is at least as effective as
warfarin in reducing thromboembolic events,2 but
might be superior to warfarin in longer follow-up
periods.3 4 LAA occlusion is now starting to appear
in treatment guidelines.5
The aim of this study was to observe the percen-
tage of thromboembolic and haemorrhagic events
over a 2-year follow-up in patients with NVAF
undergoing LAA closure with an occlusion device,
comparing observed events versus CHADS2 (con-
gestive heart failure, hypertension, age, diabetes,
stroke history), CHA2DS2-VASc (also adding vascu-
lar disease and sex) and HAS-BLED (hypertension,
abnormal liver/renal function, stroke history, bleed-
ing predisposition, labile INRs, elderly, drugs/
alcohol use)-predicted events.6–9
METHODS
The working method used in this and subsequent
studies was approved by the independent ethics com-
mittees of contributing hospitals, and all patients pro-
vided informed consent for this study. All procedures
comply with the Declaration of Helsinki. The
authors’ institutions approved the data analysis.
Patients
Closure of LAA with an ACP device (Amplatzer
Cardiac Plug, St Jude Medical, Minneapolis,
Minnesota, USA) was performed in 167 patients
with NVAF recruited from 12 hospitals between
March 2009 and early 2013. Inclusion criteria
were one or more of the following conditions:
serious haemorrhage during acenocoumarol
therapy, prior disease or clinical event that contra-
indicated OACs or repeated failure to adequately
control INR, and haematologist indication to
suspend acenocoumarol.
Implantation procedure
All patients underwent a transoesophageal echocar-
diogram (TOE) 24–48 h prior to the procedure to
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rule out the presence of LAA thrombi. One hour prior to proce-
dure, patients were given a wide-spectrum antibiotic (cephalos-
porin), and the procedure was performed under general
anaesthetic. Following transseptal puncture, patients were admi-
nistered 100 U/kg heparin. Selective angiography of the LAA
was performed with a volume similar to that of a left coronary
artery, and generally in right anterior oblique (RAO) (20°–20°)
caudal and also RAO (30°–10°) cranial views. The calibration
reference point was a 23 mm radio-opaque ball on the midaxil-
lary line. 2D TOE measurements were taken during the proce-
dure. A preliminary 40°–135° scan with the probe in
mid-oesophageal position was performed to obtain both ostium
diameters: minor (usually between 45° and 70°) and major (at
approximately 135°). The device was chosen according to the
ofﬁcial St Jude Medical scoring table, which is based on the
measurement ranges of the ostium of the LAA. As a general
rule, the size of the device was based on the length of the
longest axis of the TOE, usually the superoinferior axis. These
measurements were similar to those obtained by angiography in
the right caudal projection. In the case of borderline measure-
ments, the largest size was selected. The same operator carried
out the procedure at each hospital, and in all cases transseptal
puncture was uncomplicated; these factors, therefore, did not
affect the study variables.
Postimplantation treatment and follow-up
At the coordinating hospital, follow-up TOE was performed
1 day after intervention, and then at 1, 3, 6 and 12 months to
monitor placement of the device, the presence or absence of
interatrial shunting and absence of ﬂow to the LAA, focusing
above all on the possible presence of thrombus on the device. In
the contributing hospitals, at least two follow-up visits were per-
formed during the 6 months postimplantation. Following
implantation, a loading dose (600 mg) of clopidogrel was admi-
nistered, and treatment was started with 300 mg aspirin (ASA) on
the ﬁrst day and 100 mg daily thereafter. Clopidogrel was main-
tained for 3–6 months, barring haemorrhagic complications, and
ASA for 6–12 months. If thrombus occurred, subcutaneous enox-
aparin in a therapeutic dose was added for 2 weeks, clopidogrel
was prolonged and the TOE was repeated to check for disappear-
ance. If the result was negative, the decision to prolong the treat-
ment for another week or hospitalise the patient and begin
treatment with intravenous heparin was evaluated.
Deﬁnition of outcomes
Implantation was successful when the following criteria were
met: (a) appropriate distance between the body and the outer
disc; that is, the body of the device in the neck of the LAA and
the disc covering the ostium, with both standard angiographic
views (cranial RAO and caudal RAO) or the short-axis view
showing a clear separation between them; (b) lightly compressed
body or lobe (tyre shape) without the ‘raspberry’ effect indica-
tive of excessive compression; (c) absence of ﬂow between the
left atrium and the LAA over the device or, failing that, <3 mm
on a colour Doppler ultrasound; and (d) proof of ﬁrm ancho-
rage to the LAA using the tug test.
The main events were death, stroke, serious and relevant hae-
morrhage, and hospitalisation for concomitant conditions, mon-
itored by means of scheduled visits and telephone calls. The
International Society on Thrombosis and Haemostasis deﬁnition
was used to deﬁne major bleeding: fatal bleeding, and/or symp-
tomatic bleeding in a critical area or organ, such as intracranial,
intraspinal, intraocular, retroperitoneal, intra-articular or peri-
cardial, or intramuscular with compartment syndrome, and/or
bleeding causing a fall in haemoglobin level of 20 g/L
(1.24 mmol/L) or more, or leading to transfusion of two or
more units of whole blood or red cells.10 Minor but relevant
bleeding was deﬁned according to the Academic Research
Consortium11 guidelines as any bleeding not meeting major cri-
teria but important enough for the patient or the clinician to
merit discontinuation of antithrombotic therapy, albeit tempora-
rily: (1) The patient does not visit the doctor but can suspend
antithrombotic therapy, for example, haematoma, epistaxis, hae-
morrhoidal bleeding, and so on and (2) The patient visits the
doctor and action is needed, for example, suspension of antith-
rombotic therapy, diagnostic tests and hospitalisation.
Statistical analysis
Continuous variables are expressed as mean±SD or median
(25th–75th percentiles), depending on distribution of data.
Categorical variables were compared using χ2 or Fisher’s exact
test, and numerical variables were analysed using the Student’s t
test or the Wilcoxon test. The observed incidence of events
(number of events during the follow-up period divided by the
number of patients per year of follow-up) was calculated per
patient and year of follow-up (number of patients at the begin-
ning of the follow-up period multiplied by the mean time of
follow-up of those patients expressed in years).
The expected incidence of events in the sample was calculated
as the mean of the individual risk of each patient. Each patient
was assigned an individual risk according to a score of bleeding
and ictus risk depending on his or her CHADS2 and HAS-BLED
score, as indicated in the work by Friberg and colleagues.9
Annual risk of bleeding or stroke was based on each patient’s
CHADS2 and HAS-BLED score. Observed and expected rates of
thromboembolic and bleeding events were compared using bino-
mial tests. Event-free survival was analysed using the Kaplan–
Meier method. All data were analysed using SPSS V.19.0.
RESULTS
Characteristics of the population
Table 1 shows the baseline characteristics of the 167 patients.
None were eligible for randomised studies in OAC since these
were contraindicated for the reasons listed in table 1. The main
indications for LAA occlusion were OAC contraindication or
complications, mostly gastrointestinal (30.5%) and neurological
(22.8%). Mean age was 74.68±8.58. Median CHADS2,
CHA2DS2-VASc and HAS-BLED scores and 25th–75th percen-
tile were, respectively, 3 (2–4), 4 (3–6) and 3 (3–4).
Mean follow-up was 24 months (mean 22±8.3 months),
giving a follow-up rate of 290 patients per year. The intraproce-
dure complication rate was 5.38%, with 2.99% being central
and 2.39% vascular due to a punctured artery resulting in arter-
iovenous ﬁstula despite prolonged compression. There was one
case of migration during the procedure just after the release of
the device that was successfully captured and replaced by a
larger device; two cases of cardiac tamponade that were
resolved with pericardial puncture; and two intraoperative tran-
sient ischaemic attacks (TIAs) that left no sequelae.
Median device size was 24 (25th–75th percentile 22–25). For
size 16, the percentage of use was 6.3%; for size 18, 6.3%; for
size 20, 11.4%; for size 22, 22.2%; for size 24, 27.8%; for size
26, 16.5%, for size 28, 7% and for size 30, 2.5%. The rate of
successful implantation was 94.6%.
Table 2 shows the outcomes of raw clinical events (data not
adjusted for patient/year) over the 2-year follow-up in 158
patients with successful implants. Mortality was 10.8%, mostly
(9.5%) non-cardiac related. Bleeding was observed in 10.1% of
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subjects, 5.7% major and 4.4% relevant without meeting major
criteria, and 4.4% suffered stroke. Findings from echocardiogra-
phy controls are also shown in table 2. In all, 13 minimal peri-
prosthetic leaks were detected that did not meet the <3 mm
signiﬁcance criterion, together with 18 cases of minimal small
atrial septal defect shunts (detected by the existence of ﬂow-
passage through the interatrial septum by eco-colour Doppler
examination), which gradually disappeared on subsequent
controls.
Table 3 shows observed events and CHADS2, CHA2DS2-VASc
and HAS-BLED-predicted events at 12 and 24 months
(expressed as annual event rates, 290 patients/year).
Signiﬁcant differences in stroke events were observed during
the ﬁrst year, whereas major bleeding events were only observed
during the second year. Tables 4 and 5, respectively, show the
comparative reduction in stroke following LAA occlusion,
contrary to the CHADS2 score expected rate, and the types of
haemorrhage occurring over follow-up, mainly gastrointestinal.
Figure 1 shows the Kaplan–Meier event-free survival curve.
Table 6 shows the percentage of patients under dual platelet
therapy and/or at least one antiaggregant treatment at 12 and
24 months of follow-up.
DISCUSSION
This study in LAA occlusion with an occlusion device is one of
only three similar studies (together with the European ACP reg-
istry and the ASAP with Watchman study) with over 150
patients contraindicated for OACs, and has one of the longest
follow-up periods.12 13
The main ﬁnding is that the reduction in the rate of events
such as stroke or bleeding versus the score-predicted rate in this
patient group6–9 is signiﬁcant as of the ﬁrst and second year
postimplantation, respectively.
Reduction of expected events during follow-up
In the ﬁrst year, signiﬁcant difference between observed and
CHADS2-predicted stroke and TIA rate was observed despite
peri-implantation events and possible thrombus formation on
the devices in the ﬁrst few months. Incidence, therefore, was
3.9% (or 5.2% including peri-implantation events) versus 9.6%
expected rate. Nevertheless, at 2 years when expressed as annual
event rates, 290 patients/year, this was 2.4% versus 9.6% score-
predicted rate (p<0.001).
In the ASAP study, all-cause stroke or systemic embolism
occurred in four patients (2.3% per year): ischaemic stroke in
three patients (1.7% per year) and haemorrhagic stroke in one
patient (0.6% per year).13 In other series, stroke and TIAs are
usually separated, but in general the approximate mean percen-
tage of stroke/TIA ranged from 2% to 3% per year, a 70% reduc-
tion with respect to the score-predicted rate (table 4).2 12 14–19
Thrombus formation on the device usually occurs around the
delivery cable attaching screw, but improvements in design and
implantation techniques (faster, 100 U/kg heparin following
transseptal puncture, activated clotting time (ACT) monitoring)
will probably reduce incidence of thrombi. Most of them are
located over the upper quadrant between the screw and the left
lateral ridge; they are not usually greater than 5–10 mm and
respond well to treatment with low molecular weight heparins
for 2 weeks. Once the device is endocardiolised, thrombus for-
mation is virtually nil.
In this series, thrombus formation on the device occurred in
around 8% of patients, similar to other studies where it ranges
from 5% to 17% depending on the strictness and deﬁnition of
the TOE follow-up protocol (inclusion/exclusion of mural
thrombus).5 12–19 More importantly, thrombus rate is higher
when dual antiplatelet therapy (DAPT) is withdrawn in the ﬁrst
2 months, and usually falls with the addition of a 2–3-week
course of enoxaparin.14 18 19 Nevertheless, information on post-
implantation antithrombotic therapy is somewhat contradictory.
In the PROTECT AF study in the Watchman device,2 warfarin
was administered for the ﬁrst 45 days, followed by DAPT. In
other studies, DAPT is administered for 3 months, followed by a
further 3 months with ASA alone,14–17 19 while others report
good results with DAPT for only 6 weeks, following by indeﬁ-
nite ASA18 suggesting that DAPT is more effective than aceno-
coumarol or warfarin.18
One of the most interesting ﬁndings in this series is the
reduced incidence of bleeding, which was signiﬁcant between
the ﬁrst and second years following withdrawal of antiplatelet
drugs. Bleeding at 2 years was 10.4% (16 patients), of which
Table 2 Raw clinical events and echocardiographic findings
during follow-up in 158 successfully implanted patients
Clinical events
Death 17 (10.8%)
Major bleeding 9 (5.7%)
Minor relevant bleeding 7 (4.4%)
Total bleeding events 16 (10.1%)
Stroke/TIA 7 (4.4%)
Some event 30 (19.0%)
Echocardiographic findings
Device thrombus 13 (8.2%)
Small residual ASD 18 (11.4%)
Leak 13 (8.2%)
ASD, atrial septal defect; TIA, transient ischaemic attack.
Table 1 Baseline and procedure-associated characteristics (n=167)
Age (in years)
≥75 years: 84 (53.2%); ≥78 years: 63 (39.9%)
74.68±8.58
Men 102 (61.1%)
CHADS2 3 (2–4)
CHA2DS2-VASC 4 (3–6)
HAS-BLED 3 (3–4)
Procedure indication
Gastrointestinal haemorrhage 51 (30.5%)
Cranial haemorrhage 38 (22.8%)
Other haemorrhages 28 (16.8%)
CVA/embolism with OAC 12 (7.2%)
High risk of bleeding 7 (4.2%)
Others 32 (19.2%)
Device size (lobe diameter ranging from 16 to 30) 24 (22–25)
Need to change device* 6 (3.5%)
Successful implantation 158 (94.6%)
Procedural complications 9 (5.38%)
TIA 2 (1.2%)
Vascular complication 4 (2.39%)
Cardiac tamponade 2 (1.2%)
Device migration (percutaneously snared) 1 (0.6%)
Values expressed as: number (percentage), mean±SD or median (25th–75th
percentiles).
*Three of the changes were due to a larger size, while the other three to a smaller
size.
CVA, cerebrovascular accident; HAS-BLED, hypertension, abnormal liver/renal function,
stroke history, bleeding predisposition, labile international normalised ratios, elderly,
drugs/alcohol use; OAC, oral anticoagulant; TIA, transient ischaemic attack.
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4.4% were relevant (minor) (seven patients) and 5.7% major
(nine patients) versus a HAS-BLED-predicted rate of 6.6%
major bleeding events (NS). This is to be expected since during
the ﬁrst 6 months patients were given antiplatelet agents, and
the BAFTA and ACTIVE studies have shown that bleeding with
antiplatelet drugs is equivalent to bleeding with OAC, particu-
larly among elderly patients.20 21 Nevertheless, in the second
year, when most patients no longer took antiplatelet drugs, the
bleeding rate in this series (when expressed as annual event
rates, 290 patients/year) remained practically unchanged (3.1%
vs HAS-BLED-predicted 6.6% (p=0.047)). These ﬁndings are
wholly consistent with the longer follow-up period of the
PROTECT AF study, in which the balance of events in favour of
the implant was more noticeable during the second year.3
Relevant bleeding events are not usually shown when report-
ing major bleeding, which is on average 3%–3.6% versus minor
relevant bleeding, with an annual rate that can exceed 10%.1
Lack of information leads to underestimation of the percentage
of patients requiring suspension of therapy and the effect this
can have. This is very important since real-life studies that
include patients who would otherwise be excluded from rando-
mised series have shown that in follow-up of less than 2 years,
up to 51.4% of patients had to suspend anticoagulant therapy
due to intercurrent conditions (procedures, falls, etc) or hae-
morrhagic complications (34%),22 23 incidence of the latter
being higher with higher CHADS2 and HAS-BLED scores.
These studies showed that the risk of stroke during suspension
periods increased (OR=1.60)22 23 and in the ROCKET AF
study, the risk of thromboembolic events during suspension was
more than 6%–8%.24 Suspension after 2 years is due to bleeding
problems and poor compliance. In the PROTECT AF study, for
example, 16% did not resume warfarin after 2 years,3 and the
situation is no better with new OACs, as shown by the 21% rate
reported in the RELY study in dabigatran.
Furthermore, the fact that studies in LAA occlusion devices
usually include patients contraindicated for OACs and that the
annual rate of major bleeding in patients not included in rando-
mised studies25 is closer to 7% than the 3%–3.6% found in
these studies is widely ignored. In a review of 994 patients
treated with warfarin with some kind of bleeding, less than
70% would have been eligible for a clinical trial, and the risk of
bleeding increases dramatically with more exclusion criteria.26
Most bleeding observed during follow-up in this series was
gastrointestinal. Approximately 58% of bleeding with dabiga-
tran was gastrointestinal, and incidence was higher than with
warfarin (p<0.001).27 Annual incidence of gastrointestinal
bleeding is around 4.5% in patients taking OAC.28 Resumption
of warfarin leads to bleeding recurrence at 3 months as high as
10%, and even 5.5% without resumption.28 The 30-day mortal-
ity rate following major bleeding due to OAC is signiﬁcant,
ranging from 9.1% to 13%.27
Procedural safety
Safety events have fallen to less than half the rate reported in
the PROTECT AF study and Continued Access Protocol regis-
ter, the European ACP register and postmarket
Table 3 Observed versus expected events at 12- and 24-month follow-up, adjusted for patient/year
Events
12-month (158 patients/year)
Global follow-up (annual event rates,
290 patients/year)
Observed Expected* p Value Observed Expected* p Value
Death 9 (5.8%) 17 (5.8%)
Major bleeding 8 (5.2%) 6.6%
HAS-BLED
0.400 9 (3.1%) 6.6%
HAS-BLED
0.047
Total bleeding (major+relevant) 15 (9.5%) 16 (5.5%)
Stroke/TIA 6 (3.9%) 9.6%
CHADS2
0.007 7 (2.4%) 9.6%
CHADS2
<0.001
8.3% CHA2DS2-VASc 0.025 8.3% CHA2DS2-VASc 0.003
*Expected rates based on Friberg et al9 using event rates not adjusted for reduction by aspirin.
HAS-BLED, hypertension, abnormal liver/renal function, stroke history, bleeding predisposition, labile international normalised ratios, elderly, drugs/alcohol use; TIA, transient ischaemic
attack.
Table 4 Observed and expected events at 1 year in different studies in LAA occlusion patients contraindicated for OAC
Study name
Number of
patients CHA2DS2-VASc
Follow-up
(months)
Total stroke/TIA
follow-up Stroke %/year
%
Reduction
Death
patient/
year
Antithrombotic
therapy
Spanish Unicentre
(ACP)14
35 3.94±1.89 21.14±10.1 2.85% (1/35) 0% versus 5.45% 5.04% 3–6 m DAPT
3 m indefinite ASA
Partial ACP European
postmarket
145 3.7±1.7 24 2.12% (1/47) 1.24% versus
5.33%
65% NA 3 m DAPT 3 m ASA
USA-European
ASAP (Watch)13
150 4.4±1.7 14.4±8.6 2.6% (4/150) 1.7% vs 7.3% 77% 5% 6 m DAPT
Canadian (ACP)15 52 5 (4–6) 20±5 5.7% (3/52) 1.1% vs 8.6% 87% 5.8% 1–3 or 1–6 m
Iberian multicentre
(current)
167 4 (3–6) 22±8.3 4.2% (7/167) 2.4% vs 9.6% 75% 5.8% 3–6 m DAPT
6 m indefinite ASA
Average of figures or
percentages
549 4.2 20.38 3.54% (16/451) 1.28% vs 7.25% 76% 5.41%
ACP, Amplatzer Cardiac Plug; ASA, aspirin; DAPT, double antiplatelet therapy; LAA, left atrial appendage; OAC, oral anticoagulant; TIA, transient ischaemic attack.
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surveillance.29 30 However, recent studies in populations
similar to this series in highly experienced hospitals continue
to report rates of between 4% and 8%. The ASAP and the
Canadian study reported 8.7% and 5.8%, respectively,
although most events were resolved with few sequelae or none
at all.13 15 A complication rate of around 5.38% is average.
Vascular complications in most studies range from 1% to
2.5%. For example, the ASAP study reported 2% vascular pro-
blems and 3.8% major bleeding due to haematoma at the
puncture site, while other events such as 1.2% perioperative
TIA, 1%–2% cardiac tamponade and 0.6% device migration
are at the lower end of the rates reported in leading studies.
The authors believe that after accidental puncture of the
femoral artery the needle should not be withdrawn and com-
pression applied immediately, but rather the introducer should
remain in the artery and compression or percutaneous closure
performed at the end of the procedure as programmed as
otherwise arteriovenous haematomas and/or ﬁstulas can form.
Regarding study limitations, this study recruited 167 patients
from 12 hospitals, thereby including patients from hospitals
with varying experience in the procedure. Nevertheless, most
sites started and included cases under a common monitor, a
factor that the authors believe ensures homogeneity. Instead of
being randomised, event comparison is score-based; however,
the scores used have been thoroughly validated in the literature.
Finally, the methodological approach applied during the
follow-up period could have been more exhaustive than that
used in routine practice and in highly experienced groups.17
In conclusion, these ﬁndings show that LAA closure with an
occlusion device in patients contraindicated for OAC is a rea-
sonably safe therapeutic option associated with fewer throm-
boembolic and haemorrhagic events than those expected from
risk scores, particularly after the ﬁrst year postimplantation fol-
lowing endothelialisation and withdrawal of antiplatelet therapy.
New studies with longer follow-up periods and early disconti-
nuation of DAPT would be of great interest to verify whether
Table 5 Details of major bleeding over follow-up
Type of haemorrhage Reason for implantation Gender Age HAS-BLED Time since implantation (months) Treatment
1 Upper gastrointestinal bleeding Gastrointestinal haemorrhage F 68 3 3 ASA and clopidogrel
2 Upper gastrointestinal bleeding Gastrointestinal haemorrhage F 78 4 24 ASA and clopidogrel
3 Cerebral haematoma Cerebral haemorrhage M 73 3 6 ASA
4 Upper gastrointestinal bleeding Ischaemic CVA M 73 4 3 ASA
5 Lower gastrointestinal bleeding Lower gastrointestinal bleeding M 83 3 6 ASA and clopidogrel
6 Lower gastrointestinal bleeding Lower gastrointestinal bleeding M 70 4 12 Nothing
7 Lower gastrointestinal bleeding Severe anaemia F 78 4 12 ASA
8 Lower gastrointestinal bleeding Lower gastrointestinal bleeding M 84 4 3 ASA and clopidogrel
9 Lower gastrointestinal bleeding Lower gastrointestinal bleeding M 65 4 1 ASA and clopidogrel
ASA, aspirin; CVA, cerebrovascular accident; F, female; HAS-BLED, hypertension, abnormal liver/renal function, stroke history, bleeding predisposition, labile international normalised
ratios, elderly, drugs/alcohol use; M, male.
Figure 1 Kaplan–Meier event-free
survival curves over 24-month
follow-up.
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bleeding events during the ﬁrst year are reduced without losing
the efﬁcacy of lowering thromboembolic events. This could
broaden current indications.
Key messages
What is already known on this subject?
Left atrial appendage closure has been shown not to be inferior
to oral anticoagulants (OACs) in the treatment of patients with
non-valvular atrial ﬁbrillation, and some studies suggest it could
be a good alternative for patients contraindicated for OACs due
to high risk of haemorrhage.
What might this study add?
The reduction of events in this population with respect to
expected outcomes based on risk scores is signiﬁcant in the ﬁrst
year for stroke (53% at 12 months and 73% at 24 months) and
in the second year for haemorrhage (53%).
How might this impact on clinical practice?
Left atrial appendage closure is shown to be an effective
treatment for patients contraindicated for OACs. However, with
current antithrombotic therapy similar haemorrhagic
complications can occur in the ﬁrst year, suggesting the need to
seek alternative antithrombotic treatment and maximise
vigilance for this complication during this period.
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